Literature DB >> 15955523

Malaria vaccines. Evaluation and implementation.

Brian Greenwood1.   

Abstract

Development of an effective malaria vaccine that could be deployed widely in endemic areas has proved to be more difficult than was anticipated, when the first clinical trials of malaria vaccines were conducted 30 years ago. Substantial progress has been made during the past few years and one candidate vaccine, RTS,S/AS02, shows promise. However, during the period that malaria vaccine development has been taking place, alternative methods of malaria control including insecticide treated bednets and intermittent preventive treatment in infancy and childhood have been developed and shown to be partially effective. Malaria vaccines will need to be more effective or more cost effective than these alternative control strategies or be able to provide substantial added value, when deployed with them if they are to be adopted widely.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15955523     DOI: 10.1016/j.actatropica.2005.04.017

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  12 in total

1.  Polymeric linear Peptide chimeric vaccine-induced antimalaria immunity is associated with enhanced in vitro antigen loading.

Authors:  Luciana M Silva-Flannery; Monica Cabrera-Mora; Megan Dickherber; Alberto Moreno
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

2.  Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques.

Authors:  A Moreno; I Caro-Aguilar; S S Yazdani; A R Shakri; S Lapp; E Strobert; H McClure; C E Chitnis; M R Galinski
Journal:  Vaccine       Date:  2008-06-23       Impact factor: 3.641

3.  Characterization of a conserved rhoptry-associated leucine zipper-like protein in the malaria parasite Plasmodium falciparum.

Authors:  Silvia Haase; Ana Cabrera; Christine Langer; Moritz Treeck; Nicole Struck; Susann Herrmann; Pascal W Jansen; Iris Bruchhaus; Anna Bachmann; Suzana Dias; Alan F Cowman; Hendrik G Stunnenberg; Tobias Spielmann; Tim-Wolf Gilberger
Journal:  Infect Immun       Date:  2008-01-03       Impact factor: 3.441

4.  A combined transcriptome and proteome survey of malaria parasite liver stages.

Authors:  Alice S Tarun; Xinxia Peng; Ronald F Dumpit; Yuko Ogata; Hilda Silva-Rivera; Nelly Camargo; Thomas M Daly; Lawrence W Bergman; Stefan H I Kappe
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-02       Impact factor: 11.205

5.  Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial.

Authors:  Eusebio V Macete; Jahit Sacarlal; John J Aponte; Amanda Leach; Margarita M Navia; Jessica Milman; Caterina Guinovart; Inacio Mandomando; Yolanda López-Púa; Marc Lievens; Alex Owusu-Ofori; Marie-Claude Dubois; Conor P Cahill; Marguerite Koutsoukos; Marla Sillman; Ricardo Thompson; Filip Dubovsky; W Ripley Ballou; Joe Cohen; Pedro L Alonso
Journal:  Trials       Date:  2007-03-26       Impact factor: 2.279

Review 6.  How might infant and paediatric immune responses influence malaria vaccine efficacy?

Authors:  A M Moormann
Journal:  Parasite Immunol       Date:  2009-09       Impact factor: 2.280

7.  Characterization of immunoglobulin G antibodies to Plasmodium falciparum sporozoite surface antigen MB2 in malaria exposed individuals.

Authors:  Thanh V Nguyen; John B Sacci; Patricia de la Vega; Chandy C John; Anthony A James; Angray S Kang
Journal:  Malar J       Date:  2009-10-23       Impact factor: 2.979

8.  Malaria morbidity in high and seasonal malaria transmission area of Burkina Faso.

Authors:  Alphonse Ouédraogo; Alfred B Tiono; Amidou Diarra; Souleymane Sanon; Jean Baptiste Yaro; Esperance Ouedraogo; Edith C Bougouma; Issiaka Soulama; Adama Gansané; Amathe Ouedraogo; Amadou T Konate; Issa Nebie; Nora L Watson; Megan Sanza; Tina J T Dube; Sodiomon Bienvenu Sirima
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

9.  A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial.

Authors:  Shinji L Okitsu; Olivier Silvie; Nicole Westerfeld; Marija Curcic; Andreas R Kammer; Markus S Mueller; Robert W Sauerwein; John A Robinson; Blaise Genton; Dominique Mazier; Rinaldo Zurbriggen; Gerd Pluschke
Journal:  PLoS One       Date:  2007-12-05       Impact factor: 3.240

10.  Spatio-Temporal Variations in Malaria Incidence in Children Less than 10 Years Old, Health District of Sokone, Senegal, 2010-2013.

Authors:  Emmanuelle Espié; Fatoumata Diene Sarr; Fodé Diop; Joseph Faye; Vincent Richard; Adama Tall; Aissatou Touré Baldé
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.